



ASX Announcement

5 December 2019

## **Creso and Burleigh Heads Cannabis announce arrival of first shipment of cannaQIX® 50 in Australia**

### **Highlights**

- Creso Pharma confirms arrival of the first shipment of its innovative therapeutic product cannaQIX® 50 in Australia
- cannaQIX® 50 is now being sold in Australia as a medicinal cannabis product under the brand name 'LozaCan' via Burleighs Heads Cannabis' extensive distribution network
- Creso Pharma and Burleigh Heads Cannabis are exploring the introduction of additional therapeutic/medicinal products from Creso Pharma's pipeline of new products to the Australian market

**Creso Pharma Limited (ASX:CPH, FRA:1X8) ('Creso Pharma' or 'the Company')** is pleased to announce that it has commenced sales of its flagship medicinal cannabis product cannaQIX® 50 to Burleigh Heads Cannabis, one of Australia's leading medicinal cannabis distribution companies. Burleigh Heads Cannabis has confirmed prescriptions are already taking place and the product is receiving very positive feedback from physicians and patients.

Creso Pharma and Burleigh Heads Cannabis have placed initial focus on introducing cannaQIX® 50, which is now being sold in Australia as a therapeutic product via approved channels as 'LozaCan'. Furthermore, the two entities are exploring potentially expanding the collaboration to include additional therapeutic/medicinal products from Creso Pharma's pipeline.

cannaQIX® 50/LozaCan has been developed to Good Manufacturing Practice (GMP) standards and is produced in Switzerland by Creso Pharma's partner, Switzerland-based food and pharma development company Domaco, Dr. med Aufdermaur AG to the highest Swiss quality with a 'Swiss Made' label.

The delivery follows the recent signing of an exclusive Distribution Agreement with Burleigh Heads Cannabis and the securing of an import permit for Australia [ASX Announcement: April 30 2019]. The collaboration will enable Creso Pharma to leverage Burleigh Heads Cannabis and CDA's local regulatory experience and established distribution networks to facilitate patient access to its products in Australia.

Burleigh Heads Cannabis is a subsidiary of CDA Health Pty Ltd ('CDA'), an established Australian business supporting patient access to medical cannabis products in Australia. Through its affordable CDA-branded products and CDA Clinics, CDA assists doctors and patients navigate the process of applying, prescribing and sourcing medical cannabis legally



and provide educational resources and one-to-one service from their consultant doctors through physical and telehealth clinics. CDA has completed over 5000 successful Therapeutic Goods Administration (TGA) patient approvals since launching in October 2018.

### About cannaQIX® 50/LozaCan

cannaQIX® 50 is Creso Pharma's proprietary buccally formulated cannabidiol (CBD) lozenge which is designed to support the management of chronic pain. Each cannaQIX® 50 lozenge contains 50mg of CBD from full spectrum hemp plant extracts along with niacin, vitamins B6, B12, C, and zinc in a standardized pharma-grade formulation produced in Switzerland.

cannaQIX® 50 comes in packs of 30 lozenges in a proprietary delivery formulation designed for buccal absorption and to dissolve in the mouth. This method works faster and more efficiently than tablets or capsules which need to be swallowed and have a high percentage of their ingredients broken down when absorbed through the intestine and passed first through the liver.

By being dissolved in the mouth, the active ingredients enter the bloodstream directly, avoiding this first pass through the liver. cannaQIX® 50 lozenges taste great and are a patient-friendly way to administer precise doses of CBD when compared to oil-based alternatives.



Image 1: LozaCan cannaQIX 50®



**Dr Miri Halperin Wernli, Creso Pharma's CEO and co-founder said:** "We are pleased to announce the first delivery of cannaQIX® 50 in Australia. Burleigh Heads Cannabis and CDA Clinics Australia continue to rapidly expand their patient reach with their extensive distribution network. This close partnership enables us to fulfil our mission of bringing life-improving products to patients in Australia. We're delighted to announce this progress and look forward to further new product introductions in the near future".

**Mr Guy Headley, Managing Director for Burleigh Heads Cannabis added:** "We are delighted to mark this milestone in our collaboration with Creso Pharma. This collaboration will provide Australian patients and doctors with a quality product option to utilise for patient care. By leveraging our experience with Australian regulations and established distribution networks, we believe that we will be able to deliver an innovative product option to benefit patients across Australia."

**Ends.**

#### **Authority and Contact Details**

This announcement has been authorised for release by Dr Miri Halperin Wernli, CEO and Managing Director of Creso Pharma Limited.

For further information, please contact:

#### **Investor Enquiries**

EverBlu Capital  
E: [info@everblucapital.com](mailto:info@everblucapital.com)  
P: +61 2 8249 0000

#### **Media Enquiries**

Julia Maguire | The Capital Network  
E: [julia@thecapitalnetwork.com.au](mailto:julia@thecapitalnetwork.com.au)  
P: +61 419 815 386



### **About Creso Pharma**

Creso Pharma Limited (ASX:CPH) brings the best of cannabis to better the lives of people and animals. It brings pharmaceutical expertise and methodological rigor to the cannabis world and strives for the highest quality in its products. It develops cannabis and hemp derived therapeutic, nutraceutical, and life style products with wide patient and consumer reach for human and animal health. Creso Pharma uses GMP (Good Manufacturing Practice) development and manufacturing standards for its products as a reference of quality excellence with initial product registrations in Switzerland. It has worldwide rights for a number of unique and proprietary innovative delivery technologies which enhance the bioavailability and absorption of cannabinoids.

To learn more please visit: [www.cresopharma.com](http://www.cresopharma.com)

### **About Burleigh Heads Cannabis and Cannabis Doctors Australia (CDA) Clinics**

CDA Health Pty Ltd, through its subsidiaries, Burleigh Heads Cannabis Pty Ltd and Cannabis Doctors Australia Pty Ltd provides a market entry solution to local and international businesses seeking to gain access to Australia's Medical Cannabis market.

Burleigh Heads Cannabis is a fully licensed Medical Cannabis wholesaler which utilises its secure cold-chain facility on the Gold Coast and national pharmacy partner network to provide local and International producers a streamlined importation and distribution service throughout Australia.

CDA operates CDA Clinics, doctor-led Medical Cannabis clinics throughout Australia through its network of physical clinics and TeleHealth consultation services. CDA clinics has completed over 5000 successful TGA patient approvals since launching in October 2018.

CDA Health through CDA clinics and Burleigh Heads Cannabis provide an attractive opportunity for quality producers to effectively introduce innovative products to Australian patients.

To learn more, please visit: [www.burleighheadscannabis.com](http://www.burleighheadscannabis.com)

### **About Domaco, Dr. med Aufdermaur AG**

Domaco, Dr. med Aufdermaur AG is a Swiss-based food and pharma development company that owns the rights to a number of innovative delivery systems used to administer active ingredients through galenic forms which is a way of preparing and compounding medicines in order to optimise their absorption.

**Forward Looking statements**

This announcement contains forward-looking statements with respect to Creso and its respective operations, strategy, investments, financial performance and condition. These statements generally can be identified by use of forward-looking words such as "may", "will", "expect", "estimate", "anticipate", "intends", "believe" or "continue" or the negative thereof or similar variations.

The actual results and performance of Creso could differ materially from those expressed or implied by such statements. Such statements are qualified in their entirety by the inherent risks and uncertainties surrounding future expectations. Some important factors that could cause actual results to differ materially from expectations include, among other things, general economic and market factors, competition and government regulation.

The cautionary statements qualify all forward-looking statements attributable to Creso and persons acting on its behalf. Unless otherwise stated, all forward-looking statements speak only as of the date of this announcement and Creso has no obligation to up-date such statements, except to the extent required by applicable laws.